A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes

NCT01928329 · Completed

Last updated 2026-05-28

This clinical trial tested whether a once-weekly injection of exenatide (Bydureon®) could help improve blood sugar control in adults with type 1 diabetes.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, triple-blind treatment study

Participants 79 people

Who can join Ages 18–65 · all sexes

Timeline Started 2013-09 · est. completion 2019-08

Where 8 sites · United States

What this study is testing ClinicalTrials.gov NCT01928329 ↗

Description as written by the study sponsor.

The goal of the proposed pilot study is to determine whether glucose control can be improved with Bydureon treatment in patients with type I diabetes (T1D)

Treatments tested

Exenatide (Bydureon®) Drug
Placebo Drug

Main thing measured	Change From Baseline in HbA1c Levels
Sponsor	Yale University
Conditions studied	Type I Diabetes
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01928329 ↗